A citation-based method for searching scientific literature

Howard I Scher, Karim Fizazi, Fred Saad, Mary-Ellen Taplin, Cora N Sternberg, Kurt Miller, Ronald de Wit, Peter Mulders, Kim N Chi, Neal D Shore, Andrew J Armstrong, Thomas W Flaig, Aude Fléchon, Paul Mainwaring, Mark Fleming, John D Hainsworth, Mohammad Hirmand, Bryan Selby, Lynn Seely, Johann S de Bono. N Engl J Med 2012
Times Cited: 3002



Howard I Scher, Michael J Morris, Walter M Stadler, Celestia Higano, Ethan Basch, Karim Fizazi, Emmanuel S Antonarakis, Tomasz M Beer, Michael A Carducci, Kim N Chi, Paul G Corn, Johann S de Bono, Robert Dreicer, Daniel J George, Elisabeth I Heath, Maha Hussain, Wm Kevin Kelly, Glenn Liu, Christopher Logothetis, David Nanus, Mark N Stein, Dana E Rathkopf, Susan F Slovin, Charles J Ryan, Oliver Sartor, Eric J Small, Matthew Raymond Smith, Cora N Sternberg, Mary-Ellen Taplin, George Wilding, Peter S Nelson, Lawrence H Schwartz, Susan Halabi, Philip W Kantoff, Andrew J Armstrong. J Clin Oncol 2016
Times Cited: 700




List of shared articles



Times cited

Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 Patients.
Sungmin Woo, Chong Hyun Suh, Andreas G Wibmer, Anton S Becker, Min Yuen Teo, Mithat Gönen, Hedvig Hricak, Howard I Scher, Michael J Morris, Hebert Alberto Vargas. Clin Genitourin Cancer 2022
0

Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer.
Wietske I Luining, Matthijs C F Cysouw, Dennie Meijer, N Harry Hendrikse, Ronald Boellaard, André N Vis, Daniela E Oprea-Lager. Cancers (Basel) 2022
1

Low-Dose Enzalutamide in Metastatic Prostate Cancer-Longevity Over Conventional Survival Analysis.
Vincent Vinh-Hung, Olena Gorobets, Gilles Natchagande, Paul Sargos, Ming Yin, Nam P Nguyen, Claire Verschraegen, Edmund Folefac. Clin Genitourin Cancer 2022
0


The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide.
Renata Poteska, Kambiz Rahbar, Axel Semjonow, Andres Jan Schrader, Martin Boegemann, Katrin Schlack. BMC Cancer 2022
0

Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy.
Florian Rosar, Felix Wenner, Fadi Khreish, Sebastian Dewes, Gudrun Wagenpfeil, Manuela A Hoffmann, Mathias Schreckenberger, Mark Bartholomä, Samer Ezziddin. Eur J Nucl Med Mol Imaging 2022
3

Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial.
Thomas Powles, Kobe C Yuen, Silke Gillessen, Edward E Kadel, Dana Rathkopf, Nobuaki Matsubara, Charles G Drake, Karim Fizazi, Josep M Piulats, Piotr J Wysocki,[...]. Nat Med 2022
14